PubMed Health⌕ Search

Biomedical subjects

B Baron

Publications and source records attributed to B Baron.

79 records · Page 5Linked to original sources
PubMed1978

Levamisole in the treatment of non-invasive and invasive bladder cancer: a preliminary report.

We have done a double-blind, randomized, controlled study on 37 patients with transitional cell carcinoma in which levamisole was used as an immune adjuvant in addition to the standard therapy for non-invasive and invasive bladder cancer. Levamisole is administered easily and is well tolerated, especially when compared to other immune adjuvants, such as bacillus Calmette-Guérin or Corynecbacterium parvum. Recall antigens, dinitrochlorobenzene reactivity and total lymphocyte count demonstrated little correlation to the initial stage of disease. Monocyte chemotaxis was increased significantly in patients receiving levamisole. Since our study is ongoing on data exist as yet to make any statement regarding the efficacy of levamisole in the treatment of bladder cancer.

Aged↗
PubMedDate not supplied

Most classical Mus musculus domesticus laboratory mouse strains carry a Mus musculus musculus Y chromosome.

Restriction fragment length polymorphisms (RFLPs) of maternally inherited mitochondrial DNA have revealed that genetic exchanges can occur between populations, subspecies or even species. From the point of view of population genetics the mammalian Y chromosome represents a genomic analogue of the mitochondrion; it is inherited only paternally and remains perpetually monosomic, showing little meiotic recombination with other chromosomes. Using a Y-specific genomic DNA probe obtained from a flow-sorted mouse Y-chromosome library, we have examined the RFLPs in 10 newly established mouse lines of the European semispecies Mus musculus domesticus and Mus musculus musculus, and identified two variant forms of the Y chromosome, each of which is characteristic of one of the semispecies. As reported here, probing the DNA from nine established inbred laboratory strains reveals that the strain SJL carries a M.m. domesticus type Y whereas, surprisingly, the Y chromosomes of the other eight strains are of M.m. musculus origin. Hence, these strains cannot be regarded as archetypes of M.m. domesticus as suggested by protein polymorphisms and mitochrondrial DNA sequence data, but rather as genetic hybrids between the two semispecies.

Animals↗
PubMedDate not supplied

The use of Daphnia magna for detection of okadaic acid in mussel extracts.

Okadaic acid (OA), the main toxin responsible for diarrheic shellfish poisoning (DSP) has toxicity for Daphnia magna (EC50 = 15 +/- 1.8 micrograms/l). A Daphnia bioassay was developed and used to analyse okadaic acid in mussel extracts. A linear correlation was found between OA concentration determined by the Daphnia bioassay and by HPLC assay (r = 0.85; p < 0.001). The Daphnia bioassay can measure OA levels 10 times below the threshold of the mouse bioassay method. It is an inexpensive sensitive tool which can be used in replacement of mouse bioassay for the screening of OA and some co-extracting toxins in mussel extracts.

Animals↗
PubMedDate not supplied

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.

Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cisplatin-cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.

Antineoplastic Combined Chemotherapy Protocols↗